Search

Your search keyword '"Maxim Norkin"' showing total 4 results
Start Over Author "Maxim Norkin" Publisher american society of clinical oncology (asco)
4 results on '"Maxim Norkin"'

1. iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Author

Christopher R. Cogle, Glenda G. Anderson, Taher Abbasi, John W. Hiemenz, Biljana Horn, Kimberly E. Hawkins, Nosha Farhadfar, Helen Leather, Paul Castillo, Madeleine Turcotte, Leylah Drusbosky, John R. Wingard, Hemant S. Murthy, Fei Zou, Shireen Vali, Jack W. Hsu, Maxim Norkin, and Randy A. Brown

Subjects
Oncology, Cancer Research, Treatment response, medicine.medical_specialty, business.industry, Myelodysplastic syndromes, Myeloid leukemia, Genomics, medicine.disease, Predictive value, Clinical trial, hemic and lymphatic diseases, Internal medicine, medicine, In patient, business
Abstract

7024Background: Cytotoxic agents (7+3, HiDAC) and hypomethylating agents (HMAs) fail in the majority of MDS and AML pts. The aim of this study is to determine the predictive values of a genomics-in...

Published
2018

2. Platelet count and transfusion dependence as prognostic factors of engraftment in autologous stem cell transplantation

Author

John R. Wingard, Yu Wang, Forat Lutfi, Randy A. Brown, Maxim Norkin, Emma Rosenau, Hemant S. Murthy, and William Paul Skelton

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Incidence (epidemiology), Surgery, surgical procedures, operative, Autologous stem-cell transplantation, Oncology, Transfusion dependence, Medicine, Platelet, Stem cell, business, Complication
Abstract

e20001Background: Delayed engraftment (DE) is a well-described complication after allogeneic transplant, however the incidence and risk factors of DE in recipients of autologous stem cell transplan...

Published
2018

3. Clinical factors influencing engraftment in patients with non-Hodgkin lymphoma following autologous stem cell transplant

Author

John R. Wingard, Forat Lutfi, Randy A. Brown, Hemant S. Murthy, William Paul Skelton, Yu Wang, Maxim Norkin, and Emma Rosenau

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Standard of care, business.industry, medicine.disease, Lymphoma, Refractory, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Hodgkin lymphoma, In patient, Stem cell, business
Abstract

e19504Background: Autologous Stem Cell Transplant (ASCT) is considered as standard of care for patients (pts) with relapsed and refractory non-Hodgkin's lymphoma (NHL). In this study we evaluated d...

Published
2018

4. Striking age differences of multiple myeloma (MM) diagnosis in patients of Indian and Pakistani descent in the United States compared to native countries

Author

Abdullah Mohammad Khan, Preeti Narayan, Athira Unnikrishnan, and Maxim Norkin

Subjects
Cancer Research, education.field_of_study, Age differences, business.industry, Asian Indian, Population, Retrospective cohort study, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Medicine, Registry data, In patient, business, Male to female, education, Multiple myeloma, 030215 immunology, Demography
Abstract

e13070 Background: Several studies from India and Pakistan have reported a median younger age of MM diagnosis as compared that of western population. The exact reason for the younger age of myeloma diagnosis in this population is not well understood. Methods: We used the SEER database to analyze age of MM diagnosis in subjects of Indian and Pakistani descent in the United States and compared it to the published data of MM diagnosis in India and Pakistan. Patients with ICD—O-3 morphologic codes (9732/3) and race code 15/16/17 identifying Asian Indians and Pakistanis were identified in the SEER registry data (1973-2013). Data on year of diagnosis, race, sex and age were collected. Four published retrospective studies involving local Indians or Pakistanis patients identified using PUBMED. Average Median age and male to female ratio (M: F) was calculated in both groups and compared for any difference Results: 146 myeloma patients of either Indian or Pakistani descent were identified from the SEER registry. The median age of diagnosis was 67 years with a mean age of 66.1 years. The male to female ratio was 1.41. The retrospective studies analyzed had a total of 495 myeloma patients with median age at diagnosis of 56 years and male to female ratio of 2.01, suggesting that multiple myeloma presented almost a decade earlier in native Indian and Pakistani patients compared to their US counter parts. Conclusions: Subjects in India and Pakistan were significantly younger at the time of MM diagnosis as compared to subjects of Indian and Pakistani descent diagnosed with MM in the US suggesting an environmental factor involved with myeloma genesis in subjects living in India and Pakistan. [Table: see text]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results